Zhejiang Wecome Pharmaceutical Company Limited (300878.SZ)
CNY 18.41
(-1.13%)
CNY 18.41
(-1.13%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 105.08 Million CNY | -32.8% |
| 2022 | 156.36 Million CNY | 178.79% |
| 2021 | -198.45 Million CNY | 65.81% |
| 2020 | -580.51 Million CNY | -14456.71% |
| 2019 | 4.04 Million CNY | 131.13% |
| 2018 | -12.98 Million CNY | 83.55% |
| 2017 | -78.94 Million CNY | 14.88% |
| 2016 | -92.74 Million CNY | -110.86% |
| 2015 | -43.98 Million CNY | 14.01% |
| 2014 | -51.14 Million CNY | -309.32% |
| 2013 | -12.49 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 43.53 Million CNY | 231.01% |
| 2024 Q1 | -33.23 Million CNY | -131.62% |
| 2024 Q3 | 7.73 Million CNY | -69.65% |
| 2023 Q1 | 191.13 Million CNY | 22.24% |
| 2023 FY | 105.08 Million CNY | -32.8% |
| 2023 Q4 | 105.08 Million CNY | -55.37% |
| 2023 Q2 | -54.56 Million CNY | -128.55% |
| 2023 Q3 | 235.45 Million CNY | 531.51% |
| 2022 Q4 | 156.36 Million CNY | 275.92% |
| 2022 FY | 156.36 Million CNY | 178.79% |
| 2022 Q3 | -88.88 Million CNY | -14.76% |
| 2022 Q1 | -111.3 Million CNY | 43.92% |
| 2022 Q2 | -77.45 Million CNY | 30.41% |
| 2021 Q3 | -258.12 Million CNY | 27.98% |
| 2021 FY | -198.45 Million CNY | 65.81% |
| 2021 Q4 | -198.45 Million CNY | 23.12% |
| 2021 Q2 | -358.42 Million CNY | 24.41% |
| 2021 Q1 | -474.18 Million CNY | 18.32% |
| 2020 FY | -580.51 Million CNY | -14456.71% |
| 2020 Q4 | -580.51 Million CNY | 8.16% |
| 2020 Q2 | 46.14 Million CNY | -71.32% |
| 2020 Q1 | 160.88 Million CNY | 3878.85% |
| 2020 Q3 | -632.09 Million CNY | -1469.92% |
| 2019 Q4 | 4.04 Million CNY | 0.0% |
| 2019 FY | 4.04 Million CNY | 131.13% |
| 2019 Q1 | 83.22 Million CNY | 0.0% |
| 2018 FY | -12.98 Million CNY | 83.55% |
| 2017 FY | -78.94 Million CNY | 14.88% |
| 2016 FY | -92.74 Million CNY | -110.86% |
| 2015 FY | -43.98 Million CNY | 14.01% |
| 2014 FY | -51.14 Million CNY | -309.32% |
| 2013 FY | -12.49 Million CNY | 0.0% |